Skip to content

Brain Response Associated With Parent-based Treatment for Childhood Anxiety Disorders

Brain Response Associated With Parent-based Treatment for Childhood Anxiety Disorders

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03585010
Enrollment
214
Registered
2018-07-12
Start date
2018-08-24
Completion date
2024-03-31
Last updated
2026-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorder of Childhood, Generalized Anxiety Disorder, Separation Anxiety Disorder of Childhood, Social Anxiety Disorder of Childhood

Keywords

anxiety disorders

Brief summary

This study aims to investigate whether a parent-based treatment for childhood anxiety disorders engages child brain circuitry implicated in children's reliance on parents to reduce anxiety (R61), and whether change in child brain circuitry is associated with reduction in child anxiety (R33).

Detailed description

Specific Aims: Anxiety disorders impact up to one-third of children, cause tremendous suffering, increase risk for psychiatric and medical morbidity, impair school and social functioning, and cost billions of dollars each year. Data consistently show that child anxiety is characterized by amygdala hyperactivity and deficits in prefrontal control of the amygdala. Emerging data link these disruptions to anxious children's over-reliance on parents for amygdala-medial prefrontal cortex (mPFC) engagement and anxiety reduction. In the first phase of this study we aim to demonstrate that an entirely parent-based psychosocial treatment with no child involvement, Supportive Parenting for Anxious Childhood Emotions (SPACE), engages an amygdala-mPFC target in anxious children, lessening child reliance on parents to reduce amygdala reactivity. Cross-species neurobiological evidence indicates that parental presence reduces amygdala reactivity and activates the mPFC to reduce offspring anxiety. In humans we recently demonstrated parental presence increases functional connectivity between their child's mPFC and amygdala, reducing the child's amygdala reactivity and anxiety. In a healthy sample, parental engagement of child amygdala-mPFC connectivity was linked to the child's reliance on parents for help with anxiety. Data from clinically anxious children likewise show parental presence engages child mPFC, and data we collected since our previous submission demonstrate that parental presence reduces amygdala reactivity in clinically anxious children. Offspring's natural reliance on parents for anxiety reduction is magnified in clinically anxious children. Parents become deeply enmeshed in their child's symptoms through the process of family accommodation, defined as change in parents' behavior to help the child avoid or alleviate anxiety. In clinically anxious children, 90% report depending on parents to reduce their anxiety, and 97% of parents report accommodating their anxious child's symptoms. These cross-generational patterns of parental entanglement in their child's anxiety symptoms contribute to the immense burden, distress, and costs of pediatric anxiety (e.g., parents missing work to be with their anxious child). Anxious children's reliance on parents for anxiety reduction may disrupt the child's ability to independently reduce amygdala reactivity and anxiety. We developed SPACE to translate these neurobiological and clinical research findings into a manualized parent-based treatment focused on reducing family accommodation in parents of anxious children. Preliminary data from a randomized clinical trial show that after 12 weeks of parents receiving SPACE (N=29), with no therapist-child contact, family accommodation and child anxiety were significantly reduced. We propose that SPACE engages anxious children's amygdala-mPFC circuitry, lessening their reliance on parents to reduce amygdala reactivity. The first phase of the study will examine clinically anxious children's amygdala-mPFC response to fear faces when (A) the child's parent is beside them holding their hand during the fMRI scan (Parent-Present), and (B) the child is alone during the scan (Parent-Absent) (within-subjects design). Children with primary separation, social, or generalized anxiety disorder diagnoses, the most common childhood anxiety disorders, will serve as participants. Children will complete Parent-Present and Parent-Absent scans PRE- and POST-SPACE, or PRE- and POST-Parent Educational Support (PES), the comparator treatment that controls for treatment duration and therapist-parent contact. We expect SPACE will lessen child reliance on parental presence to engage amygdala-mPFC circuitry and reduce child amygdala reactivity. Aim 1: Demonstrate SPACE lessens children's reliance on parents to reduce amygdala reactivity (target engagement). Hyp 1: Child reliance on parental presence to reduce amygdala reactivity, (i.e., the difference between child amygdala reactivity in the Parent-Present and Parent-Absent scan), will decrease significantly from PRE- to POST-SPACE, as compared with PRE- to POST-PES. If Hyp 1 is confirmed we will proceed to the the second phase of the study. The second phase of the study will be performed to re-demonstrate target engagement in SPACE, compared to cognitive-behavioral therapy (CBT); demonstrate target engagement is associated with symptom reduction in SPACE; and demonstrate SPACE's acceptability/feasibility. The second phase will enroll clinically anxious children (7-10 yrs), randomly assigned to SPACE or CBT. Aim 1: Re-demonstrate target engagement in SPACE. Hyp 1: Child reliance on parental presence to reduce amygdala reactivity will decrease significantly from PRE- to POST-SPACE, as compared with PRE- to POST-CBT. Aim 2: Demonstrate target engagement is associated with symptom reduction in SPACE. Hyp 2: Reduction in child anxiety from PRE- to POST-SPACE will be significantly associated with reduction in child reliance on parental presence to reduce amygdala reactivity. Aim 3: Establish acceptability and feasibility of SPACE. Hyp 3: SPACE will be acceptable and feasible to administer, and comparable to CBT. The second phase will also provide insight into the relative efficacy of SPACE, to inform future research and development of SPACE. This study has the potential to provide groundbreaking results, with major public health impact, on how parent-based treatments can target disrupted neurobiological processes in children with psychopathology. These novel data will inform decision-making about a large-scale study (R01) to confirm the efficacy of SPACE and examine personalized treatment strategies.

Interventions

12 sessions with parents

12 sessions with parents

BEHAVIORALCognitive-Behavioral Therapy

12 sessions with child

Sponsors

Yale University
Lead SponsorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Assessments will conducted by independent evaluators, blind to treatment condition.

Eligibility

Sex/Gender
ALL
Age
6 Years to 12 Years
Healthy volunteers
Yes

Inclusion criteria

* Prepubertal * Clinical diagnosis of primary anxiety disorder * Must not have another mental illness more impairing than the most impairing anxiety disorder * IQ of at least 80.

Exclusion criteria

* Neurological disorders (including seizures) * Organic mental disorders, psychotic disorders, or pervasive developmental disorders * High likelihood of hurting themselves or others * Current psychosocial or psychopharmacological treatment * History of neurological illness or head injury with loss of consciousness \> 5 minutes * Vision or physical disability that interferes with seeing stimuli presented briefly on computer screen and/or clicking a mouse button rapidly and repeatedly * Contraindications for MRI scanning (e.g., metal implants, pacemakers, braces, claustrophobia, pregnancy, weight \> 250 pounds).

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline Anxiety Severity on the Pediatric Anxiety Rating Scale (PARS) at Week 12.Baseline and 12 weeksThe PARS is a clinician-administered measure of anxiety severity in children and adolescents. Total scores on PARS are used as indicator of anxiety severity. Total scores range from 0-35, with higher scores indicating more severe anxiety.

Secondary

MeasureTime frameDescription
Change From Baseline Anxiety Severity on the Multimodal Anxiety Scale for Children (MASC) at Week 12.Baseline and 12 weeksThe MASC is a self-report measure of anxiety severity, completed by children and parents separately. MASC generates a total anxiety score and several sub scales: Total scores: range from 0-150 Separation/Phobias scores: range from 0-27 Generalized anxiety scores: range from 0-30 Social anxiety scores: range from 0-27 Obsessive-compulsive symptom scores: 0-50 Physical symptoms scores: 0-60 For Total score and all sub-scales, higher scores indicate more severe anxiety. Data presented below are for the parent and child versions.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATOREli R Lebowitz, PhD

Yale University

Participant flow

Recruitment details

Participants were recruited based on physician or self-referral at Yale Child Study Center between August 2018 and October 2023. In Phase 1, the first participant was enrolled August 2018, and the last participant was enrolled in February 2020. In Phase 2, the first participant was enrolled on September 2020, and the last participant was enrolled in October 2023.

Pre-assignment details

Of 104 participants enrolled in Phase 1, 78 met inclusion criteria and were randomized to treatment; 26 were excluded (11 did not meet criteria, 6 could not complete scan, and 9 dropped before randomization). Of 205 participants enrolled in Phase 2, 136 met inclusion criteria and were randomized to treatment; 69 were excluded (27 did not meet criteria, 26 did not complete scan, 14 dropped out before randomization, and 2 did not complete assessment.)

Baseline characteristics

Characteristic
Age, Continuous8.33 years
STANDARD_DEVIATION 2.09
Ethnicity (NIH/OMB)
Hispanic or Latino
27 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
29 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
2 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
6 Participants
Race (NIH/OMB)
More than one race
4 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants
Race (NIH/OMB)
White
153 Participants
Region of Enrollment
United States
39 participants
Sex: Female, Male
Female
33 Participants
Sex: Female, Male
Male
24 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 1130 / 370 / 64
other
Total, other adverse events
0 / 1130 / 370 / 64
serious
Total, serious adverse events
0 / 1130 / 370 / 64

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 23, 2026